默沙东“转卖”科伦博泰明星ADC(抗体偶联药物)权益,是缺钱还是另有所图? 尽管手握超80亿美元现金,但在K药(Keytruda,可瑞达,通称K药,是默沙东公司研发的PD-1抑制剂类抗癌药物)专利到期倒计时、HPV疫苗收入骤降的背景下,连医药巨头也不得不重新评估每一笔研发开支。 近期,默沙东以旗下核心ADC药物sac-TMT的部分未来销售分成,向黑石集团置换7亿美元研发资金。这一动作的背后,...
Source Link默沙东“转卖”科伦博泰明星ADC(抗体偶联药物)权益,是缺钱还是另有所图? 尽管手握超80亿美元现金,但在K药(Keytruda,可瑞达,通称K药,是默沙东公司研发的PD-1抑制剂类抗癌药物)专利到期倒计时、HPV疫苗收入骤降的背景下,连医药巨头也不得不重新评估每一笔研发开支。 近期,默沙东以旗下核心ADC药物sac-TMT的部分未来销售分成,向黑石集团置换7亿美元研发资金。这一动作的背后,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.